liver as well as the recipient’s leucocyte DNA lacked FVL mutation. In case two, APCR was inherited and detected in the recipient’s liver along with the peripheral leucocyte DNA of your donor lacked the FVL mutation. Given that each patients reported no history of thrombosis, thrombophilia testing was never previously indicated. Conclusions: Consideration needs to be given to thrombophilia testing of LTX and SCTX donors and recipients which may possibly indicate anticoagulation to prevent further morbidity.PB1170|Inpatient Thrombophilia Testing Adding Unnecessary Price towards the Clot S. Bandikatla1; A. Dadlani1; A. Pinter1; S. Maharaj2; A. RojanUniversity of Louisville, Division of Internal Medicine, Louisville,United states; 2University of Louisville, Division of Medical Oncology/ Hematology, Louisville, United states of america Background: Thrombophilia testing (TT) typically features a limited role within the management of individuals with thrombosis in the inpatient setting. Inaccuracies with testing following acute thromboses or anticoagulation can result in patient anxiousness, inappropriate prolongation of anticoagulation, or false reassurance. Indiscriminate TT also adds to expense of healthcare for thrombosis. Aims: To analyze the prevalence and expense of inpatient TT and investigate whether or not the results of these tests changed management. Techniques: This was a retrospective analysis in the University of Louisville Hospital from 7/1/2020 to 12/30/2020. Patients were integrated if they were admitted with thrombosis (arterial and/or venous) and underwent inpatient TT (any test as listed in Table 1). Chart review was carried out to study demographics, details of TT, and any subsequent alter in management. Based on offered evidence and suggestions [Baglin 2010, Van Cott 2002, Pengo 2009, Nicolaides 2005], the price of inappropriate TT was assessed. Cost data had been obtained from Clinical Laboratory Fee Schedule. Results: Over the 6-month period, TT integrated 156 tests in 38 patients (average 4.1 tests/patient). The majority was female (63 ) with a imply age of 48.three years [range: 195]. The motives for TT are detailed in Table 2; recurrent VTE was by far the most frequent. Twothirds of TT (67 ) have been classed as inappropriate. Overall, six tests were positive (3.8 ); none in the constructive tests changed management. The total price of TT was estimated at 38,944; inappropriate TT was estimated at 28,165.TABLE 1 Inpatient thrombophilia tests studied – frequency and yield of BRD3 Inhibitor Source testingTest name Protein C activity Protein S activity Antithrombin III activity Element V Leiden mutation Issue V activity Prothrombin mutation MTHFR mutation TOTAL Quantity ordered 6 6 10 19 7 16 7 Quantity resulting constructive 1 two 1 0 0 0 0 156 tests 6 positive tests Test name contd. JAK2 mutation PNH flow cytometry Lupus anticoagulant dRVVT Beta-2 glycoprotein 1 Antibody (IgA/ IgG/ IgM) Anti-cardiolipin Antibody (IgA/ IgG/ IgM) Quantity ordered eight eight 17 17 17 18 Quantity resulting positive 0 0 0 0 1ABSTRACT857 of|Table 2 Charted motives for inpatient thrombophilia testing across six months in an inpatient settingCharted cause Recurrent Venous Thromboembolism (VTE) VTE in an uncommon location (cerebral, COX Inhibitor Molecular Weight splanchnic) Stroke at a young age or recurrent cryptogenic stroke/arterial thrombosis Huge Pulmonary embolism Pulmonary embolism in pregnancy Number ( ) 21 (55 ) 11 (29 ) 3 (7 ) 1(2 ) three(7 )Conclusions: Inpatient TT at an urban tertiary hospital was pricey (average estimate 1,024 per patient) having a higher price of inappropriate TT, low good outcome rate (3.eight ), an